CA Patent

CA2435835A1 — Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer

Assigned to Pharmacia LLC · Expires 2002-08-15 · 24y expired

What this patent protects

Disclosed is a method of retarding the development of polyps and prevention, inhibition and treatment of cancer in the intestine of a subject by administration of a composition comprising a peptide with the active domain of uroguanylin or any agonist peptide or compound binding t…

USPTO Abstract

Disclosed is a method of retarding the development of polyps and prevention, inhibition and treatment of cancer in the intestine of a subject by administration of a composition comprising a peptide with the active domain of uroguanylin or any agonist peptide or compound binding to the guanylate cyclase receptor GC-C in the intestine in combination with a naturally occurring, derived from a naturally occurring, or a chemically synthesized cycloogenase-2 inhibitor, preferably a selective cyclooxygenase-2 inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
CA2435835A1
Jurisdiction
CA
Classification
—
Expires
2002-08-15
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacia LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.